Elranatamab-bcmm (Elrexfio) plus mezigdomide produced preliminary response signals in patients with relapsed/refractory multiple myeloma, according to results from the phase 1b portion of the MELT-MM trial (NCT06645678) presented at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition. (Cancer Network) - Sep 24, 2026 - "At a data cutoff of July 31, 2026, and a median follow-up of 13.7 months (range, 8.6-19.3) from cycle 0, day 1, all 13 evaluable patients achieved a response for an overall response rate (ORR) of 100%, including a stringent complete response (sCR) in 12 patients (92.3%) and a very good partial response in 1 patient (7.7%). The median time to response was 17 days (range, 11-45), and the median time to best response was 5.6 months (range, 3.3-5.9). Responses were consistent across the mezigdomide 0.3-mg (n = 7) and 0.6-mg (n = 6) dose cohorts and across subgroups, including patients with prior T-cell engager exposure, triple-class–refractory disease, penta-refractory disease, and soft tissue extramedullary disease, all of which had a 100% ORR....Patient-sample analyses supported the biological rationale for the combination."
P1 data • Multiple Myeloma
|